Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001841401-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-17 | 2026-03-15 | TARS | Wahl Bryan | GC | M - OptEx | — | +24.2K | 76.4K | +46% | — |
| DM | 2026-03-17 | 2026-03-15 | TARS | Wahl Bryan | GC | M - OptEx | $0.00 | -24.2K | 14.4K | -63% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-15 | M | A | 24,236 | — | 76,399 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. |
| 2 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 7,248 | $0.00 | 7,249 | D | — · — to — | 7,248 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F5) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |
| 3 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 4,790 | $0.00 | 0 | D | — · — to — | 4,790 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F4) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. |
| 4 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 5,022 | $0.00 | 15,067 | D | — · — to — | 5,022 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F7) RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. |
| 5 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 7,176 | $0.00 | 14,351 | D | — · — to — | 7,176 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F6) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |